Royalty Pharma reports second quarter 2026 results
NEW YORK, NY, August 5, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.
News
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
NEW YORK, NY, August 3, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026.
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
NEW YORK, NY, July 22, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.
Royalty Pharma declares third quarter 2026 dividend
NEW YORK, NY, July 17, 2026 — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
NEW YORK, NY, July 15, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
NEW YORK, NY, June 4, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET.
Royalty Pharma to present at upcoming investor conferences
NEW YORK, NY, May 7, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May
Royalty Pharma reports first quarter 2026 results
NEW YORK, NY, May 6, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
NEW YORK, NY, April 21, 2026 – Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine.
Royalty Pharma Declares Second Quarter 2026 Dividend
NEW YORK, NY, April 17, 2026 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share.
